Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

118
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
118
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

659
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
659
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

174
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
174
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

544
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
544
Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model01:13

Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model

116
Drugs administered through various routes can lead to nonlinear elimination, resulting in complex pharmacokinetic behaviors crucial to understanding efficacious drug dosing.
When a drug is administered through a constant intravenous infusion and eliminated via nonlinear pharmacokinetics, it follows zero-order input. For example, oral drugs undergo first-order absorption upon administration and are eliminated through nonlinear pharmacokinetics.
In the case of subcutaneously administered drugs,...
116
Multicompartment Models: Overview01:14

Multicompartment Models: Overview

221
Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
221

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating the Risk Factors in Progression of HIV Disease Using an Illness-Death Multistate Model.

Journal of research in health sciences·2025
Same author

Evaluating the performance of different machine learning algorithms based on SMOTE in predicting musculoskeletal disorders in elementary school students.

BMC medical research methodology·2025
Same author

Global trends and projection of aetiology-based chronic kidney disease incidence from 1990 to 2030: a Bayesian age-period-cohort modelling study.

BMJ open·2025
Same author

Recovery indicators from the perspective of patients with chronic low back pain: a cross-sectional survey.

Pain management·2025
Same author

Improving sleep quality of patients undergoing hemodialysis in Iran through receiving spiritual care program: a randomized controlled trial.

Scientific reports·2025
Same author

The Effect of Three Suture Techniques for Closure of Total Knee Arthroplasty: A Clinical Trial Study.

The journal of knee surgery·2025

Related Experiment Video

Updated: Aug 23, 2025

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.4K

Zero-augmented beta-prime model for multilevel semi-continuous data: a Bayesian inference.

Naser Kamyari1, Ali Reza Soltanian2, Hossein Mahjub3

  • 1Department of Biostatistics and Epidemiology, School of Health, Abadan University of Medical Sciences, Abadan, Iran.

BMC Medical Research Methodology
|November 3, 2022
PubMed
Summary

This study introduces a flexible Bayesian two-part mixed-effects model for analyzing semi-continuous medical data, like pharmaceutical expenditure. The new model effectively handles zero-inflated and skewed data in multilevel studies.

Keywords:
Bayesian frameworkNon-negative dataPharmaceutical expenditureSkew distributionsTwo-part mixed-effects model

More Related Videos

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

11.4K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Related Experiment Videos

Last Updated: Aug 23, 2025

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.4K
A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

11.4K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Area of Science:

  • Biostatistics
  • Medical Informatics
  • Health Economics

Background:

  • Semi-continuous data with excess zeros and right-skewed positive values are common in medical research, particularly for pharmaceutical expenditure (PE).
  • Existing two-part mixed-effects models are used for clustered semi-continuous data in multilevel studies.
  • There is a need for more flexible models to accurately analyze such data structures.

Purpose of the Study:

  • To propose a novel, flexible two-part mixed-effects model for nested semi-continuous cost data using a Bayesian approach.
  • To incorporate skew distributions within the model framework for improved accuracy.
  • To evaluate the model's performance using pharmaceutical expenditure data and simulation studies.

Main Methods:

  • A Bayesian two-part mixed-effects model was developed.
  • Part I models the occurrence of positive values using a generalized logistic mixed model.
  • Part II models the magnitude of positive values using a linear mixed model with skew-distributed errors (e.g., beta-prime distribution).

Main Results:

  • The proposed model was applied to pharmaceutical expenditure data from a multilevel observational study.
  • Model performance was assessed by comparing various skew distributions using Bayesian criteria (DIC3, LPML, WAIC, LOO).
  • Simulation studies were conducted to validate the model's effectiveness.

Conclusions:

  • The proposed flexible two-part mixed-effects model provides a robust framework for analyzing semi-continuous medical cost data.
  • The Bayesian approach with skew distributions enhances the analysis of zero-inflated and skewed data in multilevel settings.
  • This methodology offers improved insights into healthcare expenditure patterns.